Tag: licensing
-
Avanir, Concert in Licensing Deal for Neurological Drugs
The biopharmaceutical company Avanir Pharmaceuticals Inc. in Aliso Viejo, California and the biotechnology firm Concert Pharmaceuticals in Lexington, Massachusetts have agreed on a deal that licenses Concert’s drug-development technology to design treatments for neurological and psychiatric disorders. While the companies did not disclose financial details, the industry Web site Xconomy says the deal can provide…
-
Biotech, GSK to Partner on Rare Inherited Cellular Diseases
Angiochem, a biotechnology company in Montreal, Canada says it will collaborate with the global pharmaceutical company GlaxoSmithKline on treatments for lysosomal storage diseases, a type of rare, inherited conditions causing cellular dysfunctions. Under the agreement, Angiochem will be eligible for at least $300 million in payments. Lysosomal storage diseases are a class of disorders caused…
-
Stem Cells Repair Heart Muscle in Clinical Trial
A clinical trial at Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins Medical Center in Baltimore has shown that treating patients with their own heart-derived stem cells helps re-grow healthy muscle damaged by a heart attack. The team led by Raj Makkar of Cedars-Sinai using technology developed by Eduardo Marbán (pictured right), director of…
-
Instrument Company to License Scripps Screening Technology
Brooks Life Science Systems, a division of Brooks Automation in Poway, California, and Scripps Research Institute in Jupiter, Florida have agreed for Brooks to commercialize technology developed at Scripps to manage compounds in high-throughput screening, a process for drug discovery. Brooks Automation is a provider of instrumentation technology for manufacturing, energy, and life sciences companies.…
-
Prostate Cancer Therapy Shown Effective in Chemo Patients
A phase 3 clinical trial has shown a new drug to treat prostate cancer is effective with patients who had previously been treated with chemotherapy. The results of the study of MDV3100 — made by the biopharmaceutical company Medivation Inc. in San Francisco and Astellas Pharma Inc. in Tokyo, Japan — will be presented tomorrow…
-
Diagnostics Company Out-Licenses Cancer Testing Technology
Health Discovery Corporation in Savannah, Georgia says it has licensed its diagnostics technology to NeoGenomics Inc. in Fort Myers, Florida to develop lab tests for blood and solid tumor cancers. The license excludes tests for breast and retina cancers, for which other companies have already acquired Health Discovery’s technology. NeoGenomics will pay Health Discovery Corporation…
-
Challenge Seeks Combat Emergency Rescue Device
A new challenge on InnoCentive calls for a concept and design of a device that enables a rescuer to quickly and safely transport an injured person away from a combat site. The contest has a prize of $15,000 and a deadline of 28 February 2012. InnoCentive in Waltham, Massachusetts is a company that conducts open-innovation…
-
Patent Awarded for Stem Cell Generation Process
A process that enables a single gene to generate millions of therapeutic stem cells from ordinary human cells has received a patent from the U.S. Patent and Trademark Office. The patent — number 8,080,420 — was awarded to medical professor Kiminobu Sugaya and colleagues at University of Central Florida in Orlando, and assigned to that…
-
Enzyme Developer In-Licenses Synthetic Biology Technology
Novozymes A/S in Bagsvaerd, Denmark has agreed to license genetic engineering technology from MorphoSys AG in Martinsried, Germany for the development of industrial biotechnology products. The multi-year agreement provides Novozymes, a manufacturer of industrial enzymes, with a non-exclusive license to use MorphoSys’s Slonomics technology. Financial and more precise timetable details of the deal were not…
-
Scientists Finding Problems Accessing Stem Cell Lines
A survey conducted by Georgia Institute of Technology in Atlanta of U.S. researchers working with stem cells suggests many scientists face road blocks, including rejected access, trying to acquire human embryonic stem cell lines. Results of the survey were published in the December issue of the journal Nature Biotechnology (paid subscription required). The survey of…